Delivering Genetic Editing Therapies To Market

By Dr. Rajiv Vaidya, Head of Manufacturing Science & Technology, and Dr. Samir Acharya, Associate Director of Process Development, Andelyn Biosciences

DNA-Neurological Research-GettyImages-1224202684

In the last decade, breakthrough approaches in genetic engineering have revolutionized therapeutic research and placed deliverable gene editing therapies within patients' grasps. Molecular tools such as CRISPR-Cas machinery and zinc finger nucleases (ZFNs) are providing the possibility for patients to overcome the effects of genetic abnormalities, which are thought to impact around 1% of the global population.

However, before these therapeutics are available to patients, there are a number of hurdles for developers to navigate as their gene editing therapies move toward clinical and commercial production. Patient safety remains at the forefront of genetic engineering practices and is pertinent for not only the application of gene editing machinery, but also the manufacturing processes involved in delivering therapies. Considering scalability and cost as therapies move toward manufacturing will also be essential to make gene editing treatments accessible to a broad number of patients.

Developers and manufacturers will need to demonstrate flexibility while staying abreast of innovations, industry advancements, and evolving regulations as the gene editing industry matures. As your company develops its genetic engineering capabilities, learn more about the steps necessary to allow commercially available gene editing therapeutics to become a reality.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene